{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:35Z","timestamp":1790753795407,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019650","name":"Vir Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005062","name":"Fujirebio Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cgh.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T21:12:25Z","timestamp":1599081145000},"page":"1933-1940.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-4610","authenticated-orcid":false,"given":"Hannah S.J.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo J.H.","family":"van Campenhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke J.","family":"van Vuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette A.P.","family":"Krassenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"de Knegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.09.004_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib2","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1002\/hep.22977","article-title":"Endpoints of therapy in chronic hepatitis B","volume":"49","author":"Feld","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.09.004_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.09.004_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib5","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","author":"Cornberg","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analog therapy in patients with chronic hepatitis b: Clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.09.004_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analog therapy: Finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.09.004_bib9","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study)","volume":"61","author":"Brouwer","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.09.004_bib10","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"30","author":"Lau","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.09.004_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon \u03b1-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.09.004_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","article-title":"High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study","volume":"50","author":"Moucari","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib13","first-page":"127A","article-title":"Addition of peginterferon alfa-2a increases HBsAg decline in HBeAg-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy: results from a multicenter randomized controlled trial. (PAS Study)","volume":"70","author":"Farag","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.09.004_bib14","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.09.004_bib15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.20128","article-title":"Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B","volume":"39","author":"Zonneveld","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.09.004_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.09.004_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1478-3231.2008.01935.x","article-title":"Treatment of HBeAg-positive patients with nucleos\/tide analogs","volume":"29","author":"Coffin","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.09.004_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B treatment: what we know now and what remains to be researched","volume":"3","author":"Suk-Fong Lok","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2020.09.004_bib21","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.09.004_bib22","article-title":"Hepatitis B surface antigen levels can be used to rule out cirrhosis in hepatitis B e antigen-positive chronic hepatitis B: results from the SONIC-B study","author":"Sonneveld","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cgh.2020.09.004_bib23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.09.004_bib24","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.09.004_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.09.004_bib26","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0168-8278(05)80425-8","article-title":"Antiviral therapy of chronic hepatitis B: past, present, and future","volume":"17","author":"Perrillo","year":"1993","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.09.004_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0168-8278(03)00156-9","article-title":"Treatment options for chronic hepatitis B not responding to interferon","volume":"38","author":"Hadziyannis","year":"2003","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520312325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520312325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:36:30Z","timestamp":1761543390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520312325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1542356520312325"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.09.004","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}